– USA, CA – Apogee Therapeutics, a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, today announced the appointments of Jennifer Fox and BJ Jones to its Board of Directors.
Ms. Fox will also chair the audit committee.
About Jennifer Fox
Jennifer Fox is an expert in biopharmaceutical corporate strategy, finance, and business development. She serves as Nuvation Bio’s CFO and a Nuvation Bio’s Executive Committee member. Before joining Nuvation Bio, Ms. Fox spent more than 25 years as a healthcare investment banker advising biotechnology and pharmaceutical companies in financing and strategic transactions. Most recently, Ms. Fox was a managing director and co-head of the Healthcare Corporate and Investment Banking Group at Citigroup. Before that, she held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America, and Prudential Securities. Ms. Fox currently serves on the board of directors and as chair of the audit committee of ProKidney Corp. and on the board of directors of Life Science Cares.
She previously served on the board of directors of the Elizabeth Glaser Pediatric AIDS Foundation. Ms. Fox holds B.S. degrees in finance and marketing from Manhattan College.
About William “BJ” Jones
BJ has more than 25 years of commercial experience in the healthcare industry and, most recently, served as CCO, migraine & common diseases at Biohaven Pharmaceuticals, which was acquired by Pfizer for $11.6 billion, and then was responsible for the company’s commercial integration. Mr. Jones has held executive leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, and NitroMed. He has significant experience in large market product launches, including Nurtec ODT, Abilify, Farxiga, Pradaxa, BiDil, and Excedrin Migraine. Mr. Jones has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, and depression), cardiovascular (congestive heart failure and atrial fibrillation), diabetes (type 2 – oral and injectable), respiratory, gastrointestinal and infectious disease. Before joining the pharmaceutical industry, Mr. Jones served eight years in the U.S. Air Force and earned the rank of Major.
He holds a B.S. in human factors engineering from the U.S. Air Force Academy, an M.Sc. in industrial engineering from Texas A&M University, and an MBA from Stanford Graduate School of Business.
About Apogee
Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for treating atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications with high unmet needs. Apogee’s antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today’s standard of care.
For more information: https://apogeetherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
